정맥내 주입 펌프 시장 규모, 점유율, 동향 분석 리포트 : 제품별, 적응 질환별, 지역별, 부문 예측(2025-2030년)

Intravenous Infusion Pumps Market Size, Share & Trends Analysis Report By Product (Volumetric Infusion Pumps, Syringe Infusion Pumps), By Disease Indication (Chemotherapy, Diabetes, Gastroenterology), By Region, And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,158,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,529,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,271,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

정맥내 주입 펌프 시장의 성장과 동향 :

Grand View Research, Inc.의 최신 보고서에 따르면 세계의 정맥내 주입 펌프 시장 규모는 2030년까지 99억 8,000만 달러에 달할 것으로 예상되며, 예측 기간 중 CAGR 8.5%로 확대될 것으로 예측됩니다.

암, 당뇨, 심혈관 질환, 호흡기 질환 등 만성질환의 유병률 증가로 인해 정확한 투약 및 치료 관리가 필요해지면서 주입 펌프 수요를 견인하고 있습니다.

세계 고령화는 특히 외래 환자 및 재택 간호 현장에서 주입 펌프의 채택을 더욱 가속화하고 있으며, 복잡한 약물 요법을 관리하는 고령 환자의 안전하고 정확한 약물전달을 촉진하고 있습니다. 세계보건기구(WHO) 보고서에 따르면 2024년 출생시 기대수명은 73.3세로 1995년 이후 8.4세 연장될 것으로 예상하고 있습니다. 또한 60세 이상 세계 인구는 2023년 11억 명에서 2030년 14억 명에 달할 것으로 예측되고 있으며, 이러한 기술의 필요성이 커지고 있음을 강조하고 있습니다.

주입 펌프 기능의 기술적 발전은 시장 수요를 크게 촉진하고 있습니다. 무선 연결, EHR 통합, 자동 프로그래밍 기능을 갖춘 스마트 주입 펌프는 투약 오류를 최소화하고 워크플로우를 간소화하여 환자의 안전과 업무 효율성을 향상시킵니다.

정맥 주입 펌프 보고서 하이라이트:

• 정량 주입 펌프는 2024년 제품 부문에서 가장 큰 시장 점유율을 차지했습니다. 대량의 수액을 정확하게 주입하는 효과는 암, 당뇨병과 같은 만성질환의 관리 및 수술에 필수적입니다.
• 인슐린 주입 펌프는 예측 기간 중 9.0% 이상의 가장 빠른 CAGR로 성장할 것으로 예측됩니다. 주로 고령화, 건강에 해로운 생활습관, 비만율 증가로 인한 전 세계 당뇨병 유병률 증가가 인슐린 펌프 수요를 주도하고 있습니다.
• 소아과/신생아과는 2024년 전체 매출의 25.0% 이상을 차지하며 질환 적응증 부문을 지배하고 있습니다.
• 화학요법 분야는 암 환자 수 증가와 암 치료제의 급속한 개발로 인해 예측 기간 중 가장 빠른 CAGR로 성장할 것으로 예측됩니다.
• 북미는 높은 의료 인프라, 만성질환 증가, 기술 발전으로 정맥주입펌프 시장을 독점하고 있습니다.
• 2024년 5월, Moog Inc.는 CURLIN 8000 Ambulatory Infusion System의 FDA 510(k) 승인을 획득했습니다. 이 새로운 멀티 테라피 플랫폼은 재택 수액 환경에서 사용 편의성과 안전성을 높이기 위해 설계되었습니다.

목차

제1장 조사 방법과 범위

제2장 개요

제3장 정맥내 주입 펌프 시장의 변수, 동향, 범위

• 시장 계통 전망
  • 모시장 전망
  • 관련/부수 시장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 정맥내 주입 펌프 시장 분석 툴
  • 업계 분석 - Porter의 산업 분석
  • PESTEL 분석
• 정맥내 주입 펌프 시장 : 파이프라인 분석

제4장 정맥내 주입 펌프 시장 : 제품 추정·동향 분석

• 제품 부문 대시보드
• 정맥내 주입 펌프 시장 : 제품 변동 분석
• 세계의 정맥내 주입 펌프 시장 규모와 동향 분석(제품별, 2018-2030년)
• 용적식 주입 펌프
• 시린지 주입 펌프
• 인슐린 주입 펌프
• 경장 주입 펌프
• 휴대용 주입 펌프
• 환자 제어식 진통제 주입 펌프
• 이식형 주입 펌프
• 기타

제5장 정맥내 주입 펌프 시장 : 질환 적응증 추정·동향 분석

• 질환 적응 부문 대시보드
• 정맥내 주입 펌프 시장 : 질환 적응증 변동 분석
• 세계의 정맥내 주입 펌프 시장 규모와 동향 분석(질환 적응증별, 2018-2030년)
• 화학요법
• 당뇨병
• 소화기 내과
• 진통/통증 관리
• 소아과·신생아과
• 혈액학
• 기타

제6장 정맥내 주입 펌프 시장 : 지역 추정·동향 분석

• 지역 시장 대시보드
• 지역별 시장 점유율 분석, 2024년·2030년
• 정맥 주입 펌프 시장 : 지역별, 주요 포인트
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 덴마크
  • 스웨덴
  • 노르웨이
• 아시아태평양
  • 중국
  • 일본
  • 인도
  • 호주
  • 한국
  • 태국
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트
  • 쿠웨이트

제7장 경쟁 구도

• 최근 동향과 영향 분석 : 주요 시장 참여 기업별
• 기업/경쟁 분류
• 벤더 구도
  • 주요 기업의 히트맵 분석, 2024년
• 기업 개요
  • Baxter
  • B. Braun Medical Inc.
  • Medtronic
  • Micrel Medical Devices SA
  • Boston Scientific Corporation
  • Cardinal Health
  • Fresenius Kabi AG
  • ICU Medical, Inc.
  • F. Hoffmann-La Roche Ltd
  • Tandem Diabetes Care, Inc.
  • Terumo Corporation
  • Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
  • Moog Inc.
  • IRadimed Corporation

KSA

영문 목차

영문목차

Intravenous Infusion Pumps Market Growth & Trends:

The global intravenous infusion pumps market size is anticipated to reach USD 9.98 billion by 2030 and is anticipated to expand at a CAGR of 8.5% during the forecast period, according to a new report by Grand View Research, Inc. The increasing prevalence of chronic conditions, including cancer, diabetes, cardiovascular, and respiratory diseases, necessitates precise medication and therapy administration, thereby driving the demand for infusion pumps.

The global aging population further amplifies the adoption of infusion pumps, particularly in outpatient and home care settings, where they facilitate safe and accurate drug delivery for elderly patients managing complex medication regimens. The World Health Organization reported that life expectancy at birth increased to 73.3 years in 2024, a rise of 8.4 years since 1995. Moreover, the global population aged 60 and older is projected to reach 1.4 billion by 2030, up from 1.1 billion in 2023, highlighting the growing need for such technologies.

Technological advancements in infusion pump capabilities significantly bolster market demand. Smart infusion pumps, featuring wireless connectivity, EHR integration, and automated programming, enhance patient safety and operational efficiency by minimizing medication errors and streamlining workflows

Intravenous Infusion Pumps Report Highlights:

• Volumetric infusion pumps held the largest market share in the product segment in 2024. Their efficacy in delivering large volumes precisely is vital in managing chronic diseases such as cancer and diabetes and in surgical procedures.
• Insulin infusion pumps are projected to grow at the fastest CAGR of over 9.0% over the forecast period. The global rise in diabetes prevalence, primarily due to aging populations, unhealthy lifestyles, and increasing obesity rates, has driven insulin pump demand.
• Pediatrics/neonatology dominated the disease indication segment with over 25.0% of the total revenue share in 2024.
• The chemotherapy segment is projected to grow at the fastest CAGR over the forecast period, driven by the rising number of cancer cases and rapid development in oncological drugs.
• North America dominated the intravenous infusion pumps market due to its advanced medical infrastructure, increasing chronic disease prevalence, and technological advancements.
• In May 2024, Moog Inc. received FDA 510(k) clearance for its CURLIN 8000 Ambulatory Infusion System. This new multi-therapy platform was designed for enhanced usability and safety in home infusion settings.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Disease Indication
  • 1.2.3. Regional scope
  • 1.2.4. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product outlook
  • 2.2.2. Disease indication outlook
  • 2.2.3. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Intravenous Infusion Pumps Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
  • 3.2.2. Market restraint analysis
• 3.3. Intravenous Infusion Pumps Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape
• 3.4. Intravenous Infusion Pumps Market: Pipeline Analysis

Chapter 4. Intravenous Infusion Pumps Market: Product Estimates & Trend Analysis

• 4.1. Product Segment Dashboard
• 4.2. Intravenous Infusion Pumps Market: Product Movement Analysis
• 4.3. Global Intravenous Infusion Pumps Market Size & Trend Analysis, by Product, 2018 to 2030 (USD Million)
• 4.4. Volumetric Infusion Pumps
  • 4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Syringe Infusion Pumps
  • 4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.6. Insulin Infusion Pumps
  • 4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.7. Enteral Infusion Pumps
  • 4.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.8. Ambulatory Infusion Pumps
  • 4.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.9. Patient-Controlled Analgesia Infusion Pumps
  • 4.9.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.10. Implantable Infusion Pumps
  • 4.10.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.11. Others
  • 4.11.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Intravenous Infusion Pumps Market: Disease Indication Estimates & Trend Analysis

• 5.1. Disease Indication Segment Dashboard
• 5.2. Intravenous Infusion Pumps Market: Disease Indication Movement Analysis
• 5.3. Global Intravenous Infusion Pumps Market Size & Trend Analysis, by Disease Indication, 2018 to 2030 (USD Million)
• 5.4. Chemotherapy
  • 5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Diabetes
  • 5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.6. Gastroenterology
  • 5.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.7. Analgesia/Pain Management
  • 5.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.8. Pediatrics/Neonatology
  • 5.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.9. Hematology
  • 5.9.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.10. Others
  • 5.10.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Intravenous Infusion Pumps Market: Regional Estimates & Trend Analysis

• 6.1. Regional Market Dashboard
• 6.2. Regional Market Share Analysis, 2024 & 2030
• 6.3. Intravenous infusion pumps market by Region: Key Takeaways
• 6.4. North America
  • 6.4.1. U.S.
    • 6.4.1.1. Key country dynamics
    • 6.4.1.2. Regulatory framework/ reimbursement structure
    • 6.4.1.3. Competitive scenario
    • 6.4.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.2. Canada
    • 6.4.2.1. Key country dynamics
    • 6.4.2.2. Regulatory framework/ reimbursement structure
    • 6.4.2.3. Competitive scenario
    • 6.4.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.3. Mexico
    • 6.4.3.1. Key country dynamics
    • 6.4.3.2. Regulatory framework/ reimbursement structure
    • 6.4.3.3. Competitive scenario
    • 6.4.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Europe
  • 6.5.1. UK
    • 6.5.1.1. Key country dynamics
    • 6.5.1.2. Regulatory framework/ reimbursement structure
    • 6.5.1.3. Competitive scenario
    • 6.5.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.2. Germany
    • 6.5.2.1. Key country dynamics
    • 6.5.2.2. Regulatory framework/ reimbursement structure
    • 6.5.2.3. Competitive scenario
    • 6.5.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.3. France
    • 6.5.3.1. Key country dynamics
    • 6.5.3.2. Regulatory framework/ reimbursement structure
    • 6.5.3.3. Competitive scenario
    • 6.5.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.4. Italy
    • 6.5.4.1. Key country dynamics
    • 6.5.4.2. Regulatory framework/ reimbursement structure
    • 6.5.4.3. Competitive scenario
    • 6.5.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.5. Spain
    • 6.5.5.1. Key country dynamics
    • 6.5.5.2. Regulatory framework/ reimbursement structure
    • 6.5.5.3. Competitive scenario
    • 6.5.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.6. Denmark
    • 6.5.6.1. Key country dynamics
    • 6.5.6.2. Regulatory framework/ reimbursement structure
    • 6.5.6.3. Competitive scenario
    • 6.5.6.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.7. Sweden
    • 6.5.7.1. Key country dynamics
    • 6.5.7.2. Regulatory framework/ reimbursement structure
    • 6.5.7.3. Competitive scenario
    • 6.5.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.8. Norway
    • 6.5.8.1. Key country dynamics
    • 6.5.8.2. Regulatory framework/ reimbursement structure
    • 6.5.8.3. Competitive scenario
    • 6.5.8.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Asia Pacific
  • 6.6.1. China
    • 6.6.1.1. Key country dynamics
    • 6.6.1.2. Regulatory framework/ reimbursement structure
    • 6.6.1.3. Competitive scenario
    • 6.6.1.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.2. Japan
    • 6.6.2.1. Key country dynamics
    • 6.6.2.2. Regulatory framework/ reimbursement structure
    • 6.6.2.3. Competitive scenario
    • 6.6.2.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.3. India
    • 6.6.3.1. Key country dynamics
    • 6.6.3.2. Regulatory framework/ reimbursement structure
    • 6.6.3.3. Competitive scenario
    • 6.6.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.4. Australia
    • 6.6.4.1. Key country dynamics
    • 6.6.4.2. Regulatory framework/ reimbursement structure
    • 6.6.4.3. Competitive scenario
    • 6.6.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.5. South Korea
    • 6.6.5.1. Key country dynamics
    • 6.6.5.2. Regulatory framework/ reimbursement structure
    • 6.6.5.3. Competitive scenario
    • 6.6.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.6. Thailand
    • 6.6.6.1. Key country dynamics
    • 6.6.6.2. Regulatory framework/ reimbursement structure
    • 6.6.6.3. Competitive scenario
    • 6.6.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 6.7. Latin America
  • 6.7.1. Brazil
    • 6.7.1.1. Key country dynamics
    • 6.7.1.2. Regulatory framework/ reimbursement structure
    • 6.7.1.3. Competitive scenario
    • 6.7.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.2. Argentina
    • 6.7.2.1. Key country dynamics
    • 6.7.2.2. Regulatory framework/ reimbursement structure
    • 6.7.2.3. Competitive scenario
    • 6.7.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 6.8. MEA
  • 6.8.1. South Africa
    • 6.8.1.1. Key country dynamics
    • 6.8.1.2. Regulatory framework/ reimbursement structure
    • 6.8.1.3. Competitive scenario
    • 6.8.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.8.2. Saudi Arabia
    • 6.8.2.1. Key country dynamics
    • 6.8.2.2. Regulatory framework/ reimbursement structure
    • 6.8.2.3. Competitive scenario
    • 6.8.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.8.3. UAE
    • 6.8.3.1. Key country dynamics
    • 6.8.3.2. Regulatory framework/ reimbursement structure
    • 6.8.3.3. Competitive scenario
    • 6.8.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.8.4. Kuwait
    • 6.8.4.1. Key country dynamics
    • 6.8.4.2. Regulatory framework/ reimbursement structure
    • 6.8.4.3. Competitive scenario
    • 6.8.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Recent Developments & Impact Analysis, By Key Market Participants
• 7.2. Company/Competition Categorization
• 7.3. Vendor Landscape
  • 7.3.1. Key company heat map analysis, 2024
• 7.4. Company Profiles
  • 7.4.1. Baxter
    • 7.4.1.1. Company overview
    • 7.4.1.2. Financial performance
    • 7.4.1.3. Product benchmarking
    • 7.4.1.4. Strategic initiatives
  • 7.4.2. B. Braun Medical Inc.
    • 7.4.2.1. Company overview
    • 7.4.2.2. Financial performance
    • 7.4.2.3. Product benchmarking
    • 7.4.2.4. Strategic initiatives
  • 7.4.3. Medtronic
    • 7.4.3.1. Company overview
    • 7.4.3.2. Financial performance
    • 7.4.3.3. Product benchmarking
    • 7.4.3.4. Strategic initiatives
  • 7.4.4. Micrel Medical Devices SA
    • 7.4.4.1. Company overview
    • 7.4.4.2. Financial performance
    • 7.4.4.3. Product benchmarking
    • 7.4.4.4. Strategic initiatives
  • 7.4.5. Boston Scientific Corporation
    • 7.4.5.1. Company overview
    • 7.4.5.2. Financial performance
    • 7.4.5.3. Product benchmarking
    • 7.4.5.4. Strategic initiatives
  • 7.4.6. Cardinal Health
    • 7.4.6.1. Company overview
    • 7.4.6.2. Financial performance
    • 7.4.6.3. Product benchmarking
    • 7.4.6.4. Strategic initiatives
  • 7.4.7. Fresenius Kabi AG
    • 7.4.7.1. Company overview
    • 7.4.7.2. Financial performance
    • 7.4.7.3. Product benchmarking
    • 7.4.7.4. Strategic initiatives
  • 7.4.8. ICU Medical, Inc.
    • 7.4.8.1. Company overview
    • 7.4.8.2. Financial performance
    • 7.4.8.3. Product benchmarking
    • 7.4.8.4. Strategic initiatives
  • 7.4.9. F. Hoffmann-La Roche Ltd
    • 7.4.9.1. Company overview
    • 7.4.9.2. Financial performance
    • 7.4.9.3. Product benchmarking
    • 7.4.9.4. Strategic initiatives
  • 7.4.10. Tandem Diabetes Care, Inc.
    • 7.4.10.1. Company overview
    • 7.4.10.2. Financial performance
    • 7.4.10.3. Product benchmarking
    • 7.4.10.4. Strategic initiatives
  • 7.4.11. Terumo Corporation
    • 7.4.11.1. Company overview
    • 7.4.11.2. Financial performance
    • 7.4.11.3. Product benchmarking
    • 7.4.11.4. Strategic initiatives
  • 7.4.12. Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
    • 7.4.12.1. Company overview
    • 7.4.12.2. Financial performance
    • 7.4.12.3. Product benchmarking
    • 7.4.12.4. Strategic initiatives
  • 7.4.13. Moog Inc.
    • 7.4.13.1. Company overview
    • 7.4.13.2. Financial performance
    • 7.4.13.3. Product benchmarking
    • 7.4.13.4. Strategic initiatives
  • 7.4.14. IRadimed Corporation
    • 7.4.14.1. Company overview
    • 7.4.14.2. Financial performance
    • 7.4.14.3. Product benchmarking
    • 7.4.14.4. Strategic initiatives

관련자료